Original articleClinicalRemission of Severe Relapsing or Persistent Lupus Nephritis Using Mycophenolate Mofetil
Introduction
The therapy of severe lupus nephritis (LN), mainly that of proliferative glomerulonephritis or membranous glomerulonephritis with proliferative changes (classes IV or Vb of the WHO), usually consists of high-dose prednisone and cyclophosphamide as immunosuppressive drugs. The therapeutic protocol developed more than 20 years ago at the National Institutes of Health (NIH, Bethesda, MD) is the most usual one employed in this type of nephritis (1). However, some patients have persistent activity or after a period of remission they have relapsing disease, which leads them to receive additional courses of the same drugs. Although the efficacy of this scheme as compared to high-dose steroids is proven, the toxicity due to this therapy is high and morbidity and mortality account for permanent damage or even death (2).
Mycophenolate mofetil, an inhibitor of the de novo pathway of purine synthesis in lymphocytes (3), is a useful immunosuppressive that has broadened its indications from preventing transplant rejection (4) to its use in several autoimmune diseases including lupus nephritis (5). The actions of this drug are multiple and include selective depletion of both T and B lymphocytes, reduced expression of adhesion molecules, diminished expression of inducible nitric oxide synthase and reduced proliferation of mesangial cells 6, 7. In the first randomized study comparing it to cyclophosphamide as inductor of remission, the efficacy of MMF was comparable to the one using oral CYC, as well as the relapse rate, but with less toxicity when using MMF (8). An interim follow-up report, however, showed that MMF patients tended to relapse later at a higher rate than those treated with the usual scheme (9).
In this report, we present the first cases treated in our center with MMF as reinduction therapy in persistent or relapsing cases of LN. We also report on their follow-up after they stopped MMF due to inability to continue due to cost. As far as we know, this is the first formal report using MMF for LN in Latin America. Our population is comparable in terms of disease behavior to Afro-Americans, a subset of patients who are prone to a less favorable course. Therefore, we believe that this communication is especially interesting for Latin American centers that treat lupus patients.
Section snippets
Materials and Methods
From May 2000 to February 2002, seven Mexican mestizo LN patients presenting with relapsing or persistent LN (except for one patient, see below) in spite of adequate therapy or due to serious side effects with azathioprin or CYC (either oral or IV) were offered MMF as induction or reinduction therapy. All fulfilled the American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) (10). The characteristics of the patients are summarized in Table 1. The majority of
Results
Patient's demographic characteristics at the beginning of treatment are shown in Table 1. There were six females and one male, with a mean age at the inclusion of this study of 34 ± 11 years. Two patients did not have biopsy performed due to the above-mentioned reasons. Two patients had relapsing disease after being inactive, four had persistent disease in spite of adequate treatment and patient 6 had de novo renal disease. The mean time of disease evolution at the start of MMF was 82.7 ± 63.7
Discussion
In recent years, the awareness that CYC therapy for LN can be very toxic (2) has led to the search for different treatment options, both for induction of remission and its maintenance.
MMF is a prodrug that after conversion to the active compound, mycophenolic acid, exerts different actions leading to improvement of renal function both in animal models and patients. In a study of MMF as induction drug, patients who received it for 6 months at a maximal dose of 2 g qd had a similar outcome in
Acknowledgments
The author wants to thank Isabel Balderas, M.D. for her collaboration in the initial phase of the study. The author is also deeply indebted to Antonio Villa, M.D. for help with the statistical analysis, Roche Mexico, especially through Ms. Jaqueline Haces and Noé Soria, M.D. The Women's Volunteer Committee from the Instituto Nacional de Ciencias Médicas y Nutrición provided the MMF to the patients.
References (16)
- et al.
Mycophenolate mofetil in lupus glomerulonephritis
Am J Kidney Dis
(2002) - et al.
Mycophenolate mofetil and its mechanisms of action
Immunopharmacology
(2000) - et al.
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs
N Engl J Med
(1986) - et al.
Infectious complications in SLE after immunosuppressive therapies
Curr Opin Rheumatol
(2003) - et al.
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation
Drugs
(1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
Transplantation
(1996)- et al.
Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice
Lupus
(2002) - et al.
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
N Engl J Med
(2000)
Cited by (10)
Mycophenolate Mofetil in Low Doses Stabilizes and Improves Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Lupus Nephritis
2008, Archives of Medical ResearchCitation Excerpt :In addition to its immunosuppressive effects, MMF has also been shown to prevent or at least ameliorate progressive renal scarring and fibrosis in rats (2), which could explain its potential to slow down the progression of chronic renal failure in both lupus nephritis and AAV (14,15). In combination with prednisolone, MMF was shown to be effective and well tolerated in induction of remission in severe, mostly proliferative, lupus nephritis (16–20) and membranous lupus nephritis (21). The aim of our retrospective study was to assess the efficacy and safety of MMF in the unselected population of patients with AAV and LN.
Treatment of Proliferative Lupus Nephritis-A Critical Approach
2007, Seminars in Arthritis and RheumatismCitation Excerpt :The interest of MMF in autoimmune disorders was first suggested by the encouraging results from some animal studies, which found MMF effective in attenuating autoimmune disease in murine models of SLE (22-24). Accumulating evidence derived from case reports and single-center short series has suggested that MMF may be a real option for the induction phase in patients with PLN, leading to successful remission, even in severe cases (25-27). This drug has become more attractive for clinicians and patients because it seems to offer a high efficacy and a better adverse effect profile, particularly less ovarian toxicity compared with CYC, and the lack of any nephrotoxicity.
Lupus nephritis: Induction therapy in severe lupus nephritis-should MMF be considered the drug of choice?
2013, Clinical Journal of the American Society of NephrologyMycophenolate in refractory and relapsing lupus nephritis
2014, American Journal of NephrologyTreatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil
2012, Pediatric Nephrology